Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281982 · ClinicalTrials.gov registry record
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
A clinical trial, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- 2
- Enrollment target
NCT01281982: Clinical Trial study, sponsored by National Cancer Institute (NCI).
NCT01281982 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01281982 was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
Background: \- The blood-brain barrier helps to protect the central nervous system (brain and spinal cord) from harmful toxins, but also prevents potentially useful chemotherapy from reaching brain tumors. The barrier is formed by tight connections between blood vessel cells and molecules found on the surface of brain blood vessels such as Permeability-glycoprotein (Pgp). Pgp may influence whether patients with brain tumors known as gliomas respond to chemotherapy and what side effects they may experience. The compound (11C)N-desmethyl-loperamide ((11C)dLop) reacts to Pgp molecules, and therefore may be used with positron emission tomography (PET) imaging to study the blood brain barrier. Objectives: \- To study the ability of PET imaging with (11C)dLop to evaluate the blood brain barrier in brain tumor patients. Eligibility: \- Individuals at least 18 years of age who have a brain tumor with characteristics that may be imaged with techniques such as magnetic resonance imaging (MRI) andPET. Design: * Participants will be screened with a full physical examination and medical history, blood and urine tests, and tumor imaging studies (fluorodeoxyglucose PET and MRI scans with contrast agent). * The (11C)dLop scan will take 1 hour to perform. Participants will be asked to return for blood and urine tests approximately 24 hours after the PET scan. * Participants will have followup visits at least every 4 months by repeating a complete history and physical exam and brain MRI. Participants may have repeat scans with (11C)dLop at various points in the course of cancer treatment, but will not have these scans more than twice in a 12-month period. * Participants will be followed for as long as possible during treatment to see if imaging with (11C)dLop correlates with response to the treatments.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-01-13 |
| Est. Completion | 2012-09-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281982
The ClinicalTrials.gov registry entry for NCT01281982 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01281982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281982 about?
NCT01281982 is a clinical study titled "(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas". Background: \- The blood-brain barrier helps to protect the central nervous system (brain and spinal cord) from harmful toxins, but also prevents potentially useful chemotherapy from reaching brain tumors. The barrier is formed by tight connections between blood vessel cells and molecules found on ...
What is the current status of trial NCT01281982?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2011-01-13. Estimated completion is 2012-09-24.
Who is sponsoring clinical trial NCT01281982?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.